<DOC>
	<DOCNO>NCT02422498</DOCNO>
	<brief_summary>The study do find result pre-treatment biopsy predict response cisplatin radiation treatment patient metastatic recurrent triple negative breast cancer .</brief_summary>
	<brief_title>Homologous Recombination Repair Status Biomarker Response Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin Radiation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologicallyconfirmed invasive triple negative breast cancer ( ER &lt; 1 % , PR &lt; 1 % , her2neu 01+ IHC FISHnegative ) determine MD discretion Radiation recurrent metastatic site clinically indicate would consider standard care palliation locoregional control Age ≥18 year Tumor irradiate measurable RECIST 1.1 PRC Willingness undergo tumor biopsy prior initiation treatment Life expectancy great 6 month ECOG performance status 02 Any prior chemotherapy allow include prior treatment platinumcontaining chemotherapy Prior treatment FDAapproved investigational biologics novel molecularly target therapy , include oral IV formulation , permit . Patients must prior target therapy least 14 day prior study biopsy . Use effective mean contraception woman childbearing potential Ability comprehend sign inform consent Adequate organ marrow function within 14 day prior study entry , define : Absolute neutrophil count ( ANC ) &gt; 1000/mm3 Hemoglobin &gt; 9 gm/dl Platelets &gt; 100,000/mm3 Serum creatinine &lt; 1.5 mg/dl OR creatinine clearance ≥ 50 cc/min SGOT/SGPT &lt; 2.5X institutional ULN ( &lt; 5X ULN know liver metastasis ) Unmeasurable target tumor site RECIST 1.1 PRC ( ex : lesion &lt; 2 cm CT MR scan , leptomeningeal disease , ascites , pleural/pericardial effusion , lymphangitis , nonFDGavid skin lesion ) Brain metastasis require focal whole brain radiation exclude , lesion biopsied life expectancy &lt; 6 month . Inability obtain biopsy tumor deem study Interventional Radiologist Prior chemotherapy complete &lt; 7 day prior plan study entry Prior RT allow must complete 7 day plan study entry . Note : For reirradiation case , standard departmental guideline follow exceed normal tissue Life expectancy le 6 month Intercurrent illness major medical condition comorbid condition might affect study participation ( uncontrolled renal , pulmonary hepatic dysfunction infection ) Renal dysfunction cisplatin dose would consider unsafe . Women study must neither pregnant nursing expect become pregnant therapy . For premenopausal woman , negative pregnancy test within 14 day RT require . Concurrent active malignancy nonmelanomatous skin cancer carcinoma insitu cervix , unless treatment previous cancer complete &gt; 2 year prior study entry patient remain diseasefree .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treated Concurrent Cisplatin</keyword>
	<keyword>Treated Radiation Therapy</keyword>
	<keyword>Homologous Recombination Repair Status</keyword>
	<keyword>Biomarker Response</keyword>
	<keyword>15-032</keyword>
	<keyword>Patients</keyword>
</DOC>